Your browser doesn't support javascript.
loading
A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates.
Stone, V M; Hankaniemi, M M; Laitinen, O H; Sioofy-Khojine, A B; Lin, A; Diaz Lozano, I M; Mazur, M A; Marjomäki, V; Loré, K; Hyöty, H; Hytönen, V P; Flodström-Tullberg, M.
Afiliación
  • Stone VM; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Hankaniemi MM; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Laitinen OH; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Sioofy-Khojine AB; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Lin A; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Diaz Lozano IM; Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Mazur MA; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Marjomäki V; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Loré K; Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.
  • Hyöty H; Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Hytönen VP; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Flodström-Tullberg M; Fimlab Laboratories, Tampere, Finland.
Sci Adv ; 6(19): eaaz2433, 2020 05.
Article en En | MEDLINE | ID: mdl-32494709
Coxsackievirus B (CVB) enteroviruses are common human pathogens known to cause severe diseases including myocarditis, chronic dilated cardiomyopathy, and aseptic meningitis. CVBs are also hypothesized to be a causal factor in type 1 diabetes. Vaccines against CVBs are not currently available, and here we describe the generation and preclinical testing of a novel hexavalent vaccine targeting the six known CVB serotypes. We show that the vaccine has an excellent safety profile in murine models and nonhuman primates and that it induces strong neutralizing antibody responses to the six serotypes in both species without an adjuvant. We also demonstrate that the vaccine provides immunity against acute CVB infections in mice, including CVB infections known to cause virus-induced myocarditis. In addition, it blocks CVB-induced diabetes in a genetically permissive mouse model. Our preclinical proof-of-concept studies demonstrate the successful generation of a promising hexavalent CVB vaccine with high immunogenicity capable of preventing CVB-induced diseases.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Coxsackievirus / Miocarditis Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Sci Adv Año: 2020 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Coxsackievirus / Miocarditis Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Sci Adv Año: 2020 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Estados Unidos